Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-1241 SAD and Metformin Interaction Study
NCT03061981Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vanoglipel in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Dong-A ST. Primary endpoint: Safety and Tolerability Assessments. Started Mar 2017; status: completed.
02
Drugs
vanoglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03061981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061981.